Chimerism does not predict for outcome after alemtuzumab based conditioning

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Artz A, Pollyea D, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954–964.

  2. 2

    van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728–5738.

  3. 3

    Michaelis L, Sher D, Myers M, Siddiqui M, Collins-Jones D, Ulaszek J et al. Prognostic significance of WT-1 levels in patients with myelodysplastic syndrome and leukemia after reduced-intensity allogeneic transplantation [abstract]. Proc Am Soc Clin Oncol 2006; 24: 6524a.

  4. 4

    Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H et al. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 2005; 105: 3035–3041.

  5. 5

    Huisman C, De Weger RA, Devries L, Tilanus MLJ, Verdonck LF . Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285–291.

Download references

Author information

Correspondence to K van Besien.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Michaelis, L., Lin, S., Joseph, L. et al. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant 40, 181 (2007) doi:10.1038/sj.bmt.1705707

Download citation

Further reading